Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020

Udgivet den 29-04-2020  |  kl. 13:15  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day.  The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8473556, approximately 15 minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company.  We bring energy and invention to a world in need of diagnostic truth.  Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease.  The T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Novo præsenterer data ved konference for blodsygdomme i USA
Novo/Sydbank: Ikke den store overraskelse at Zepbound giver større vægttab end Wegovy
Vestas får amerikansk ordre på 342 MW
Vestas får kursklø efter finansdirektørs exit
Tryg varsler milliardudbytter og et forsikringsresultat på over 8 mia. kr. i 2027
 

Seneste nyheder

17:48 Europa/aktier: Trodsede fransk regeringskrise og tunge danske aktiedrop
17:36 Tryg vil flekse muskler i ny strategiperiode med fokus på skala
17:18 Vestas dykker til laveste niveau siden corona: Investorer taber værdi på 12 mia. kr.
17:05 Onsdagens aktier: Tunge Mærsk, Vestas og Carlsberg trak i minus
17:00 Onsdagens obligationer: Meget rolig rente trods skuffende data fra USA
16:33 Amerikanske olielagre faldt langt mere end ventet i sidste uge
16:22 Mindre rente- og dollarfald efter skuffende amerikansk nøgletal
16:07 General Motors nedskriver 5 mia. dollar på sin problemramte kinesiske forretning
15:42 USA/åbning: Stimen ser ud til at fortsætte med årets 56. rekord i sigte
15:36 Direktør i USA's største sygekasse skudt på gaden i New York
15:22 ECB's Lagarde ser svagere økonomisk vækst og usikre udsigter
14:51 ADP-rapporten skuffede lidt i november: USA's arbejdsmarked er dog stadig i god gænge
14:12 USA/tendens: Sigter mod årets 56. rekord for S&P 500
13:26 Novo/Sydbank: Ikke den store overraskelse at Zepbound giver større vægttab end Wegovy
13:12 Coloplast frasælger kerneprodukter i hudplejeforretningen
13:06 Novo sættes til vægs af ærkerival: Wegovy giver mindst vægttab
12:57 Europa/aktier: Trodser fransk regeringskrise og holder lille plus
12:39 Kursfald i NKT giver attraktiv indgangsvinkel for den tålmodige investor mener Danske Bank
12:19 Trygs topchef: Konservatisme har gjort os godt i turbulent periode
12:11 Obligationer/middag: Fortsat dans på stedet